UBS, acting through its London branch, successfully completed its issuance of (i) CHF 310 million aggregate principal amount of 2.385 per cent. Notes due 2025, and (ii) CHF 150 million aggregate principal amount of 2.550 per cent. Notes due 2029, in
Tags :sx1
Ironwood Pharmaceuticals (Nasdaq: IRWD), a healthcare company specializing in GI treatments, and VectivBio Holding (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on developing innovative therapies for severe rare gastrointestinal conditions, have reached an agreement where&
The Board of Directors of St.Galler Kantonalbank proposes Cornelia Stengel, attorney-at-law, as a member of the Board of Directors at the Annual General Meeting on 1 May 2024. Prof. Dr. iur. Cornelia Stengel has worked as
Fidinam & Partners, the national and international tax advisory division of the Fidinam Group, appoints two new members to its Board of Directors: Giuseppe Lerose (pictured left) and Marco Moschen (pictured right). Already deputy directors
Charles Russell Speechlys has welcomed to its partnership Robert Avis (pictured) from its Private Wealth Disputes practice in Switzerland, Geneva, effective 1 May 2023. The promotion of Avis was one of 6 partnership promotions announced by the firm.
Private investment house Ardian entered into an agreement to invest in the Swiss Flowable Holding and its subsidiaries (“Mimacom Flowable Group”) along
Legal advisors involved in the UBS-Credit Suisse merger: For UBS: Freshfields Bruckhaus Deringer (‘Freshfields’) is advising UBS Group as global transaction counsel. UBS counsel also include Bär & Karrer and Davis Polk. For Credit
Niederer Kraft Frey advised Clariant in connection with its new CHF 450 million sustainability-linked syndicated revolving credit facility agreement with Skandinaviska Enskilda Banken, Citibank, BNP Paribas, Commerzbank, Credit Suisse, Deutsche Bank and UBS acting as bookrunners
UNISERS, a Swiss semiconductor metrology company that identifies invisible contamination-caused defects in semiconductor materials, raised $14M in Seed funding led by Intel Capital, with participation from M Ventures, RSBG Ventures and Swisscom Ventures. UNISERS is
Lenz & Staehelin has advised investment bank Jefferies as underwriter in the public offering of shares of the Lausanne based ADC Therapeutics, a commercial-stage biotechnology company helping to improve the lives of those affected by
